Retinoids and their receptors in cancer development and chemoprevention

Critical Reviews in Oncology/Hematology

Volumn 41, Issue 1, 2002, Pages 41-55

  Sun, Shi Yong ^a   Lotan, Reuben ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Chemoprevention; Receptors; Retinoids

Indexed keywords

CARCINOGEN; CELL NUCLEUS RECEPTOR; FENRETINIDE; ISOTRETINOIN; RECEPTOR SUBTYPE; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID; RETINOID X RECEPTOR;

ACTINIC KERATOSIS; ANIMAL MODEL; BASAL CELL CARCINOMA; BLADDER CANCER; BREAST CANCER; BRONCHUS CANCER; CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL TRANSFORMATION; CELL TYPE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; DYSPLASIA; EPITHELIUM CELL; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; LARYNX CANCER; LEUKOPLAKIA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; METAPLASIA; NEVUS; NONHUMAN; OVARY CANCER; PRECANCER; PROMYELOCYTIC LEUKEMIA; RETINOL DEFICIENCY; REVIEW; SECOND CANCER; SIGNAL TRANSDUCTION; SKIN CANCER; UTERINE CERVIX CANCER; XERODERMA PIGMENTOSUM;

ANIMALS; ANTICARCINOGENIC AGENTS; HUMANS; NEOPLASMS; RECEPTORS, RETINOIC ACID; RETINOIDS;

EID: 0036142502     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00144-5     Document Type: Review

References (123)

1. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids)
2. Cellular biology and biochemistry of the retinoids
3. Retinoids and their receptors in differentiation, embryogenesis and neoplasia
4. Retinoid and apoptosis: implication for cancer chemoprevention and therapy
5. Retinoid-induced apoptosis in normal and neoplastic tissues
6. Retinoids in chemoprevention and differentiation therapy
7. Retinoids in cancer chemoprevention
8. Retinoids and cancer in experimental animals
9. Retinoids and human cancer
10. A decade of molecular biology of retinoic acid receptors
11. The retinoid receptors
12. The nuclear receptor superfamily: the second decade
13. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression
14. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression
15. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase
16. Increasing the complexity of coactivation in nuclear receptor signaling
17. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3
18. Histone deacetylase activity is required for full transcriptional repression by mSin3A
19. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors
20. Recruitment of p300/CBP in p53-dependent signal pathways
21. Binding and modulation of p53 by p300/CBP coactivators
22. Orphan nuclear receptors - new ligands and new possibilities
23. Tissue changes following deprivation of fat-soluble vitamin A
24. Reversal of methylcholanthrene-induced changes in mouse prostates in vitro by retinoic acid and its analogues
25. Dietary vitamin A and human lung cancer
26. Altered retinoic acid receptors
27. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia
28. Molecular genetics of acute promyelocytic leukemia
29. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications
30. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
31. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17)
32. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers
33. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation
34. Aberrant expression and function of retinoid receptors in cancer
35. Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues
36. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin
37. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development
38. Analysis of retinoic acid receptor beta expression in normal and malignant laryngeal mucosa by a sensitive and routineapplicable reverse transcription-polymerase chain reaction enzyme-linked immunosorbent assay method
39. Expression of retinoid receptor genes and proteins in non-small-cell lung cancer
40. Tumor-suppressive effect of the retinoic acid receptor beta in human epidermoid lung cancer cells
41. Lung tumors in mice expressing an antisense RARbeta2 transgene
42. Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis
43. Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer
44. Loss of retinoic acid receptor-beta expression is an early event during esophageal carcinogenesis
45. Differential expression of nuclear retinoid receptors in normal and malignant prostates
46. Decreased expression of retinoic acid receptors, transforming growth factor beta, involucrin, and cornifin in cervical intraepithelial neoplasia
47. Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity
48. Dominant negative mutant of retinoic acid receptor alpha inhibits retinoic acid-induced P19 cell differentiation by binding to DNA
49. High frequency of retinoic acid receptor beta abnormalities in human lung cancer
50. Human lung cancer cell lines exhibit resistance to retinoic acid treatment
51. Implication of RARB in epidermoid (squamous) lung cancer
52. Abnormal expression of retinoic acid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma cell lines
53. Retinoic acid-mediated repression of human papillomavirus 18 transcription and different ligand regulation of the retinoic acid receptor beta gene in non-tumorigenic and tumorigenic HeLa hybrid cells
54. Retinoic acid receptor isoform RARγ1: an antagonist of the transactivation of the RARβ RARE in epithelial cell lines and normal human keratinocytes
55. Transcriptional regulation of retinoic acid receptor β in retinoic acid-sensitive and -resistant P19 embryocarcinoma cells
56. Functional inhibition of retinoic acid response by dominant negative retinoic acid receptor mutants
57. Inhibition of ligand induced promoter occupancy in vivo by a dominant negative RXR
58. A cyclic AMP response element is involved in retinoic acid-dependent RARβ2 promoter activation
59. E1A functions as a coactivator of retinoic acid-dependent retinoic acid receptor-β2 promoter activation
60. Activation of the retinoic acid receptor beta gene by 5-aza-2′-deoxycytidine in human DLD-1 colon carcinoma cells
61. Demethylation by 5-aza-2′-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells
62. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer
63. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells
64. DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2′-deoxycytidine
65. Hypermethylation of multiple genes in pancreatic adenocarcinoma
66. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas
67. Evidence for impaired retinoic acid receptor-thyroid hormone receptor AF-2 cofactor activity in human lung cancer
68. Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP-TF and their heterodimerization
69. Expression of retinoic acid nuclear receptors and tissue transglutaminase is altered in various tissues of rats fed a vitamin A-deficient diet
70. Effect of retinoid status on alpha, beta and gamma retinoic acid receptor mRNA levels in various rat tissues
71. Anti-retinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression
72. Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a
73. Placebo-controlled trial of 13-cis-retinoic acid activity on retinoic acid receptor-beta expression in a population at high risk: implications for chemoprevention of lung cancer
74. Nuclear retinoid acid receptor beta in bronchial epithelium of smokers before and during chemoprevention
75. Retinoic acid promotion of papilloma formation in mouse skin
76. Differential effects of retinoic acid and 7,8-benzoflavone on the induction of mouse skin tumors by the complete carcinogenesis process and by the initiation-promotion regimen
77. The first stage and complete promoting activity of retinoic acid but not the analog RO-10-9359
78. Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses
79. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study
80. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients
81. The effects of topical tretinoin on dysplastic nevi
82. Effects of topical tretinoin on dysplastic nevi
83. 13-cis-retinoic acid in the treatment of oral leukoplakia
84. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis
85. Risk factors for lung cancer and for intervention effects in CARET, the beta-carotene and retinol efficacy trial
86. Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance
87. Retinoid modulation of biomarkers in oral leukoplakia/dysplasia
88. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment
89. Topical application of vitamin A to oral leukoplakia: a clinical case series
90. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia
91. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide
92. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia
93. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium
94. Long-term follow-up of larynx leukoplakia under treatment with retinyl palmitate
95. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract
96. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial
97. Highlights of the cancer chemoprevention studies in China
98. Chemoprevention of cancer of uterine cervix: a study on chemoprevention of retinamide II from cervical precancerous lesions
99. Synthetic retinoids in dermatology
100. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
101. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck
102. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up
103. Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study
104. Adjuvant treatment of stage I lung cancer with high-dose vitamin A
105. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer
106. Can fenretinide protect women against ovarian cancer?
107. 13-cis-retinoic acid in chemoprevention of superficial bladder cancer. The National Bladder Cancer Group
108. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland
109. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma
110. Differences in uptake and metabolism of retinoic acid between estrogen receptor-positive and -negative human breast cancer cells
111. Recent developments in receptor-selective retinoids
112. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand
113. Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-tocopherol
114. Liarozole potentiates the cancer chemopreventive activity of and the up-regulation of gap junctional communication and connexin43 expression by retinoic acid and beta-carotene in 10T1/2 cells
115. Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors
116. Retinoic acid metabolism and inhibition of cell proliferation: an unexpected liaison
117. Toxicity and antitumor activity of liposome-entrapped retinoid Ro13-7410
118. Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid
119. Altered metabolism of all-trans-retinoic acid in liposome-encapsulated form
120. Liposome encapsulated vitamin A compounds exhibit greater stability and diminished toxicity
121. GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide
122. Inhaled isotretinoin (13-cis retinoic acid) is an effective lung cancer chemopreventive agent in A/J mice at low doses: a pilot study
123. Topical delivery of 13-cis-retinoic acid by inhalation up-regulates expression of rodent lung but not liver retinoic acid receptors